OncoMatch/Clinical Trials/NCT07280832
Phase I/II Clinical Study of JMT108 Injection for the Treatment of Advanced Malignant Melanoma and Urinary Tract Tumors
Is NCT07280832 recruiting? Yes, currently enrolling (Sep 2026). This Phase 1/2 trial studies JMT108 for unresectable locally advanced or metastatic melanoma.
Treatment: JMT108 — This is an open-label, multicenter Phase I/II clinical study conducted in participants with unresectable locally advanced or metastatic melanoma and urinary tract tumors, aiming to evaluate the safety, tolerability, pharmacokinetic characteristics, and efficacy of JMT108 Injection in this population. The study consists of Phase I and Phase II (including Phase IIa and Phase IIb), where Phase I is the dose-escalation stage, Phase IIa is the dose-expansion stage, and Phase IIb is the cohort-expansion stage.
Check if I qualifyExtracted eligibility criteria
Treatments studied
Other
Cancer type
Melanoma
Performance status
ECOG 0–1(Restricted strenuous activity)
Prior therapy
Cannot have received: IL-2/IL-15 cytokine therapy
Prior use of IL-2/IL-15 cytokine therapy
Lab requirements
Blood counts
Kidney function
Liver function
Participants with adequate organ functions
Structured fields extracted by AI. May contain errors — verify against the official protocol.
Frequently asked questions
Is NCT07280832 currently recruiting?
Yes, this trial is currently recruiting patients.
Are there prior therapy exclusions?
Yes. Prior IL-2/IL-15 cytokine therapy disqualifies patients from enrollment.
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualifyRelated pages